EyePoint Pharmaceuticals, Inc.
EYPTEyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Drugs in Pipeline
8
Phase 3 Programs
5
Upcoming Catalysts
4
Next Catalyst
Jun 30, 2026
10dMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
EYP-1901 Phase 3 Est. Readout
Primary completion for EYP-1901 trial (NCT06668064) in Wet Age Related Macular Degeneration
Source3 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
FAI Insert administered using the Mk II inserter
Non-Infectious Uveitis
EYP-1901
Diabetic Macular Edema
FAI insert
Non-Infectious Uveitis
Aflibercept (2.0 mg)
Wet Age Related Macular Degeneration
Sham Injection
Posterior Uveitis
AKB-9778
Nonproliferative Diabetic Retinopathy
Aflibercept 2mg/0.05mL Inj,Oph
Wet Age-related Macular Degeneration
Latanoprost ophthalmic solution
Ocular Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FAI Insert administered using the Mk II inserter | Phase 3 | Non-Infectious Uveitis | - | - |
EYP-1901 | Phase 3 | Diabetic Macular Edema | - | - |
FAI insert | Phase 3 | Non-Infectious Uveitis | - | - |
Aflibercept (2.0 mg) | Phase 3 | Wet Age Related Macular Degeneration | - | - |
Sham Injection | Phase 3 | Posterior Uveitis | - | - |
AKB-9778 | Phase 2 | Nonproliferative Diabetic Retinopathy | - | - |
Aflibercept 2mg/0.05mL Inj,Oph | Phase 2 | Wet Age-related Macular Degeneration | - | - |
Latanoprost ophthalmic solution | Phase 2 | Ocular Hypertension | - | - |